Ett Big Pharma avtal värt uppemot 30 miljarder kr inom Alzemheimer & Svåra neurologiska sjukdomar
http://www.firstwordpharma.com/node/1372553?tsid=28®ion_id=6#axzz45XOYUOYm “Allergan agreed to license global rights from Sosei’s Heptares Therapeutics unit to a portfolio of subtype-selective muscarinic receptor agonists being developed for the treatment of major neurological disorders, including Alzheimer’s disease, under a deal potentially worth up to $3.3 billion, the companies announced. As part of the agreed terms, Allergan will make an upfront payment of $125 million to Heptares, with the latter eligible to receive further milestones of up to approximately $665 million related to the development and launch of the first three licensed compounds for multiple indications. In addition, Heptares stands to receive up to approximately $2.5 billion linked to annual sales thresholds of these compounds. The companies added that Heptares is also eligible to receive up to double-digit tiered royalties on net sales of all products resulting from the partnership. " " ...